DE69915634D1 - Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen - Google Patents

Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen

Info

Publication number
DE69915634D1
DE69915634D1 DE69915634T DE69915634T DE69915634D1 DE 69915634 D1 DE69915634 D1 DE 69915634D1 DE 69915634 T DE69915634 T DE 69915634T DE 69915634 T DE69915634 T DE 69915634T DE 69915634 D1 DE69915634 D1 DE 69915634D1
Authority
DE
Germany
Prior art keywords
sulphonamides
tricyclic
inhibitors
derivatives
matrix metalloproteinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69915634T
Other languages
English (en)
Other versions
DE69915634T2 (de
Inventor
Michael O'brien
Armand Picard
Robert Sliskovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69915634D1 publication Critical patent/DE69915634D1/de
Application granted granted Critical
Publication of DE69915634T2 publication Critical patent/DE69915634T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/31—Distributed metering or calculation of charges
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/49—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/80—Rating or billing plans; Tariff determination aspects
    • H04M15/8044—Least cost routing
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/83—Notification aspects
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/01—Details of billing arrangements
    • H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/46—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
    • H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
DE69915634T 1998-07-30 1999-06-02 Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen Expired - Fee Related DE69915634T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9500698P 1998-07-30 1998-07-30
US95006P 1998-07-30
PCT/US1999/012273 WO2000006561A1 (en) 1998-07-30 1999-06-02 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases

Publications (2)

Publication Number Publication Date
DE69915634D1 true DE69915634D1 (de) 2004-04-22
DE69915634T2 DE69915634T2 (de) 2004-08-12

Family

ID=22248526

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69915634T Expired - Fee Related DE69915634T2 (de) 1998-07-30 1999-06-02 Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen

Country Status (32)

Country Link
US (2) US6420408B1 (de)
EP (1) EP1100792B1 (de)
JP (1) JP2002521478A (de)
KR (1) KR20010072089A (de)
CN (1) CN1310716A (de)
AP (1) AP2001002037A0 (de)
AT (1) ATE261954T1 (de)
AU (1) AU758619B2 (de)
BG (1) BG105185A (de)
BR (1) BR9912600A (de)
CA (1) CA2335077A1 (de)
DE (1) DE69915634T2 (de)
DK (1) DK1100792T3 (de)
EA (1) EA200100158A1 (de)
EE (1) EE200100063A (de)
ES (1) ES2216614T3 (de)
GE (1) GEP20033052B (de)
HR (1) HRP20010078A2 (de)
HU (1) HUP0102714A3 (de)
ID (1) ID27192A (de)
IL (1) IL140746A0 (de)
IS (1) IS5810A (de)
NO (1) NO20010479L (de)
NZ (1) NZ509439A (de)
OA (1) OA11589A (de)
PL (1) PL345776A1 (de)
PT (1) PT1100792E (de)
SK (1) SK1192001A3 (de)
TR (1) TR200100239T2 (de)
WO (1) WO2000006561A1 (de)
YU (1) YU6701A (de)
ZA (1) ZA200100455B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
PL372212A1 (en) * 2001-08-03 2005-07-11 Schering Corporation Novel gamma secretase inhibitors
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
KR100966705B1 (ko) * 2001-12-20 2010-06-29 브리스톨-마이어스 스큅 컴퍼니 β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체
EP1549306A4 (de) * 2002-06-11 2007-06-06 Wyeth Corp Substituierte phenylsulfonamid-hemmer der beta-amyloid-produktion
MXPA05000754A (es) * 2002-07-17 2005-04-19 Warner Lambert Co Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib.
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
WO2004087042A2 (en) 2003-04-04 2004-10-14 Yeda Research And Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US20060112494A1 (en) * 2004-12-01 2006-06-01 David Oppong Method of protecting an animal skin product from metalloproteinase activity
CA2678304A1 (en) * 2007-02-23 2008-08-28 Yeda Research And Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8012947B2 (en) * 2007-03-15 2011-09-06 Hospital For Special Surgery Methods and compositions for promoting wound healing
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
CA2676946A1 (en) 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
WO2012038944A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
CN114981251B (zh) * 2020-01-21 2023-11-21 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH517064A (de) * 1969-07-09 1971-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten
CH530389A (de) * 1970-03-20 1972-11-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäureamiden
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
EP0828726B1 (de) 1995-06-02 2001-10-04 Warner-Lambert Company Trizyklische verbindungen als matrix-metalloproteinase inhibitoren
US5883940A (en) 1996-07-01 1999-03-16 Teledynamics Group, Inc. Interactive method and apparatus for the generation of leads
DE69731642T2 (de) 1996-08-16 2005-12-01 Warner-Lambert Co. Llc Buttersäure matrix-metalloproteinase-inhibitoren
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos
KR20000068415A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
IL129147A0 (en) * 1996-10-16 2000-02-17 American Cyanamid Co The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Also Published As

Publication number Publication date
CA2335077A1 (en) 2000-02-10
HUP0102714A2 (hu) 2002-01-28
JP2002521478A (ja) 2002-07-16
NO20010479D0 (no) 2001-01-29
AU4329299A (en) 2000-02-21
HUP0102714A3 (en) 2003-01-28
EE200100063A (et) 2002-06-17
WO2000006561A1 (en) 2000-02-10
CN1310716A (zh) 2001-08-29
DK1100792T3 (da) 2004-07-05
ZA200100455B (en) 2002-01-16
IL140746A0 (en) 2002-02-10
EP1100792B1 (de) 2004-03-17
AP2001002037A0 (en) 2001-03-31
KR20010072089A (ko) 2001-07-31
SK1192001A3 (en) 2002-02-05
NZ509439A (en) 2002-10-25
EA200100158A1 (ru) 2001-08-27
HRP20010078A2 (en) 2002-02-28
US6420408B1 (en) 2002-07-16
BR9912600A (pt) 2001-05-02
BG105185A (en) 2002-04-30
YU6701A (sh) 2003-12-31
TR200100239T2 (tr) 2001-05-21
PT1100792E (pt) 2004-08-31
EP1100792A1 (de) 2001-05-23
ATE261954T1 (de) 2004-04-15
IS5810A (is) 2001-01-12
PL345776A1 (en) 2002-01-02
DE69915634T2 (de) 2004-08-12
OA11589A (en) 2004-07-30
ID27192A (id) 2001-03-08
ES2216614T3 (es) 2004-10-16
US20020169164A1 (en) 2002-11-14
NO20010479L (no) 2001-01-29
US6492422B2 (en) 2002-12-10
GEP20033052B (en) 2003-08-25
AU758619B2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
DE69915634D1 (de) Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen
ATE295361T1 (de) Dimerverbindungen und als inhibitoren der neuramidinase
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE69739003D1 (de) Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
DE59704640D1 (de) Sulfonamide und ihre Verwendung
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE69838903D1 (de) Sulfonamidderivate als Wirkstoff-Vorläufer von Inhibitoren der Aspartyl-Protease
ATE319686T1 (de) Mutilin-derivate und ihre anwendung als antibakterielle mittel
DE60223916D1 (de) Mikropartikelschutz von therapeutischen mittel
DE69929983D1 (de) Trifluoromethylpyrrolcarboxamide und ihre anwendung als fungizide
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
ATE277902T1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
DE59912795D1 (de) Substituierte Benzamide und ihre Verwendung als Immunmodulatoren
DE69728139T2 (de) Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
DE69801878T2 (de) Verwendung von Oxamatderivaten als Depigmentierungsmittel
DE69814894D1 (de) Isochinolin derivate als urokinase inhibitoren
ATE229034T1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
DE69802692D1 (de) Derivate der chinoloncarbonsäure
DE69902295T2 (de) Mischungen von dispersionsfarbstoffen
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
DE60204024D1 (de) 9a-n-[n'-(phenylsulfonyl)carbamoyl] derivate von 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a und von 5-o-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide a
DE60022125D1 (de) Tiefstkühlen von Waren
DE60020583D1 (de) Synchronisierung von pcm und pseudozufallstaktgebern

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER VERTRETER IST ZU ERGAENZEN IN: KROHN, S., DIPL.-CHEM. DR.RER.NAT., PAT.-ASS., 79108 FREIBURG

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee